Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

42. Testosterone treatment and risk of venous thromboembolism: population based case-control study. (Full text)

Testosterone treatment and risk of venous thromboembolism: population based case-control study.  To determine the risk of venous thromboembolism associated with use of testosterone treatment in men, focusing particularly on the timing of the risk. Population based case-control study SETTING:  370 general practices in UK primary care with linked hospital discharge diagnoses and in-hospital procedures and information on all cause mortality. 19 215 patients with confirmed venous thromboembolism (...) (comprising deep venous thrombosis and pulmonary embolism) and 909 530 age matched controls from source population including more than 2.22 million men between January 2001 and May 2013. Three mutually exclusive testosterone exposure groups were identified: current treatment, recent (but not current) treatment, and no treatment in the previous two years. Current treatment was subdivided into duration of more or less than six months. Rate ratios of venous thromboembolism in association with current

2016 BMJ PubMed

43. Testosterone Therapy Among Prostate Cancer Survivors (Full text)

Testosterone Therapy Among Prostate Cancer Survivors The use of testosterone in men with a history of prostate cancer remains controversial in light of established findings linking androgens to prostate cancer growth. However, hypogonadism significantly affects quality of life and has negative sequelae, and the risks and benefits of testosterone therapy might be worthwhile to consider in all men, even those with a history of high-risk prostate cancer.To discuss the effects of testosterone (...) on the prostate and the use of testosterone therapy in hypogonadal men with a history of prostate cancer.Review of the literature examining the effects of testosterone on the prostate and the efficacy and safety of exogenous testosterone in men with a history of prostate cancer.Summary of effects of exogenous and endogenous testosterone on prostate tissue in vitro and in vivo, with a focus on effects in men with a history of prostate cancer.Testosterone therapy ameliorates the symptoms of hypogonadism

2016 Sexual medicine reviews PubMed

44. Is Testosterone Detrimental to Renal Function? (Full text)

Is Testosterone Detrimental to Renal Function? 29318206 2019 02 26 2468-0249 1 4 2016 Nov Kidney international reports Kidney Int Rep Is Testosterone Detrimental to Renal Function? 306-310 10.1016/j.ekir.2016.07.004 Filler Guido G Department of Paediatrics, Children's Hospital at London Health Science Centre, London, Ontario, Canada. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada. Department of Medicine, University of Western Ontario

2016 Kidney international reports PubMed

45. Testosterone Treatment in Older Men. (PubMed)

Testosterone Treatment in Older Men. 27406354 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 90 10.1056/NEJMc1603665 Snyder Peter J PJ Ellenberg Susan S SS Farrar John T JT eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):88 27406355 N Engl J Med. 2016 Jul 7;375(1):89-90 27406358 (...) N Engl J Med. 2016 Jul 7;375(1):88-9 27406356 N Engl J Med. 2016 Jul 7;375(1):89 27406357 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406354 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA5

2016 NEJM

46. Testosterone Treatment in Older Men. (Full text)

Testosterone Treatment in Older Men. 27406355 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88 10.1056/NEJMc1603665 Perls Thomas T TT Boston University School of Medicine, Boston, MA thperls@bu.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug (...) therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406355 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA1

2016 NEJM PubMed

47. Testosterone Treatment in Older Men. (Full text)

Testosterone Treatment in Older Men. 27406356 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88-9 10.1056/NEJMc1603665 Stavropoulos Konstantinos K Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Boutari Chrysoula C Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Imprialos Konstantinos K Aristotle University of Thessaloniki (...) , Thessaloniki, Greece kostasimprialos@hotmail.com. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406356 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA2

2016 NEJM PubMed

48. Testosterone Treatment in Older Men. (Full text)

Testosterone Treatment in Older Men. 27406357 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89 10.1056/NEJMc1603665 Mata Douglas A DA Brigham and Women's Hospital, Boston, MA dmata@bwh.harvard.edu. Ramasamy Ranjith R University of Miami Miller School of Medicine, Miami, FL. Lipshultz Larry I LI Baylor College of Medicine, Houston, TX. eng Letter Comment United States N Engl J Med 0255562 0028-4793 (...) 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406357 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA3

2016 NEJM PubMed

49. Testosterone Treatment in Older Men. (Full text)

Testosterone Treatment in Older Men. 27406358 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89-90 10.1056/NEJMc1603665 Laurent Michaël R MR KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Antonio Leen L KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Vanderschueren Dirk D KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406358 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA4

2016 NEJM PubMed

50. Predicting low testosterone in aging men: a systematic review (Full text)

Predicting low testosterone in aging men: a systematic review Physicians diagnose and treat suspected hypogonadism in older men by extrapolating from the defined clinical entity of hypogonadism found in younger men. We conducted a systematic review to estimate the accuracy of clinical symptoms and signs for predicting low testosterone among aging men.We searched the MEDLINE and Embase databases (January 1966 to July 2014) for studies that compared clinical features with a measurement of serum (...) testosterone in men. Three of the authors independently reviewed articles for inclusion, assessed quality and extracted data.Among 6053 articles identified, 40 met the inclusion criteria. The prevalence of low testosterone ranged between 2% and 77%. Threshold testosterone levels used for reference standards also varied substantially. The summary likelihood ratio associated with decreased libido was 1.6 (95% confidence interval [CI] 1.3-1.9), and the likelihood ratio for absence of this finding was 0.72 (95

2016 EvidenceUpdates PubMed

51. Establishing a Framework - Does Testosterone Supplementation Help Older Men? (PubMed)

Establishing a Framework - Does Testosterone Supplementation Help Older Men? 26886526 2016 03 02 2018 12 02 1533-4406 374 7 2016 Feb 18 The New England journal of medicine N. Engl. J. Med. Establishing a Framework--Does Testosterone Supplementation Help Older Men? 682-3 10.1056/NEJMe1600196 Orwoll Eric S ES From the Department of Medicine, Oregon Health and Science University, Portland. eng Editorial Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J (...) Med. 2016 Feb 18;374(7):611-24 26886521 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 2 18 6 0 2016 2 18 6 0 2016 3 5 6 0 ppublish 26886526 10.1056/NEJMe1600196

2016 NEJM

52. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Rights OpenAccess. This work is licensed under a Creative

2016 PURLS

53. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy

Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Bu B Yeap, Mathis Grossmann, Robert I McLachlan, David J Handelsman, Gary A Wittert, Ann J Conway, Bronwyn GA Stuckey, Douglas W Lording, Carolyn A Allan, Jeffrey D Zajac and Henry G Burger Med J Aust 2016; 205 (4

2016 MJA Clinical Guidelines

54. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline

Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline Guidelines CMAJ ©2015 8872147 Canada Inc. or its licensors CMAJ 1 CME T estosterone deficiency syndrome, also known as late-onset hypogonadism, is a clinical and biochemical syndrome that can occur in men in association with advancing age. The condition is characterized by deficient testicular production of testosterone. It may affect multiple organ systems and can result in substantial health (...) consequences. 1 The management of testosterone deficiency syndrome in men is associated with much contro- versy, creating confusion and reluctance among health practitioners in dealing with the subject. A small number of professional bodies 2,3 have pub- lished guidelines on the topic, yet a multidisci- plinary guideline with specific Can adian content did not exist. This is relevant because there are important differences in health care systems com- pared with other jurisdictions in North America

2015 CPG Infobase

55. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. (Full text)

Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Infertility is a condition affecting 10% to 15% of couples of reproductive age. It is generally defined as "the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse". The treatment of infertility may involve manipulation of gametes or of the embryos themselves. These techniques are together known as assisted reproductive technology (ART (...) ). Practitioners are constantly seeking alternative or adjunct treatments, or both, in the hope that they may improve the outcome of assisted reproductive techniques. This Cochrane review focusses on the adjunct use of synthetic versions of two naturally-produced hormones, dehydroepiandrosterone (DHEA) and testosterone (T), in assisted reproduction.DHEA and its derivative testosterone are steroid hormones proposed to increase conception rates by positively affecting follicular response to gonadotrophin

2015 Cochrane PubMed

56. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Rights OpenAccess. This work is licensed under a Creative

2015 PURLS

57. Testosterone and "Age-Related Hypogonadism" - FDA Concerns. (PubMed)

Testosterone and "Age-Related Hypogonadism" - FDA Concerns. 26287846 2015 08 25 2016 11 25 1533-4406 373 8 2015 Aug 20 The New England journal of medicine N. Engl. J. Med. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. 689-91 10.1056/NEJMp1506632 Nguyen Christine P CP From the Food and Drug Administration, Silver Spring, MD. Hirsch Mark S MS Moeny David D Kaul Suresh S Mohamoud Mohamed M Joffe Hylton V HV eng Journal Article United States N Engl J Med 0255562 0028-4793 3XMK78S47O (...) Testosterone AIM IM Advertising as Topic Age Factors Aged Cardiovascular Diseases chemically induced Drug Industry Drug Labeling legislation & jurisprudence Government Regulation Humans Hypogonadism drug therapy Male Middle Aged National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division Off-Label Use Testosterone adverse effects blood therapeutic use United States United States Food and Drug Administration 2015 8 20 6 0 2015 8 20 6 0 2015 8 26 6 0 ppublish 26287846 10.1056

2015 NEJM

58. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. (Full text)

Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. Testosterone use in older men is increasing, but its long-term effects on progression of atherosclerosis are unknown.To determine the effect of testosterone administration on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels.Testosterone's Effects on Atherosclerosis (...) Progression in Aging Men (TEAAM) was a placebo-controlled, double-blind, parallel-group randomized trial involving 308 men 60 years or older with low or low-normal testosterone levels (100-400 ng/dL; free testosterone <50 pg/mL), recruited at 3 US centers. Recruitment took place between September 2004 and February 2009; the last participant completed the study in May 2012.One hundred fifty-six participants were randomized to receive 7.5 g of 1% testosterone and 152 were randomized to receive placebo gel

2015 JAMA PubMed

59. Comparative Safety of Testosterone Dosage Forms (Full text)

Comparative Safety of Testosterone Dosage Forms Increases in testosterone use and mixed reports of adverse events have raised concerns about the cardiovascular safety of testosterone. Testosterone is available in several delivery mechanisms with varying pharmacokinetics; injections cause spikes in testosterone levels, and transdermal patches and gels cause more subtle but sustained increases. The comparative cardiovascular safety of gels, injections, and patches has not been studied.To (...) determine the comparative cardiovascular safety of testosterone injections, patches, and gels.A retrospective cohort study was conducted using administrative claims from a commercially insured (January 1, 2000, to December 31, 2012) and Medicare (January 1, 2007, to December 31, 2010) population in the United States and general practitioner records from the United Kingdom (January 1, 2000, to June 30, 2012). Participants included men (aged ≥18 years) who initiated use of testosterone patches, gels

2015 EvidenceUpdates PubMed

60. Testosterone in Men with Erectile Dysfunction with No Symptoms of Hypogonadism

Testosterone in Men with Erectile Dysfunction with No Symptoms of Hypogonadism Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Testosterone in Men with Erectile Dysfunction

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review